Literature DB >> 33572655

Programmed Death-Ligand 2 Deficiency Exacerbates Experimental Autoimmune Myocarditis in Mice.

Siqi Li1, Kazuko Tajiri1, Nobuyuki Murakoshi1, DongZhu Xu1, Saori Yonebayashi1, Yuta Okabe1, Zixun Yuan1, Duo Feng1, Keiko Inoue1, Kazuhiro Aonuma1, Yuzuno Shimoda1, Zoughu Song1, Haruka Mori1, Honglan Huang2, Kazutaka Aonuma1, Masaki Ieda1.   

Abstract

Programmed death ligand 2 (PD-L2) is the second ligand of programmed death 1 (PD-1) protein. In autoimmune myocarditis, the protective roles of PD-1 and its first ligand programmed death ligand 1 (PD-L1) have been well documented; however, the role of PD-L2 remains unknown. In this study, we report that PD-L2 deficiency exacerbates myocardial inflammation in mice with experimental autoimmune myocarditis (EAM). EAM was established in wild-type (WT) and PD-L2-deficient mice by immunization with murine cardiac myosin peptide. We found that PD-L2-deficient mice had more serious inflammatory infiltration in the heart and a significantly higher myocarditis severity score than WT mice. PD-L2-deficient dendritic cells (DCs) enhanced CD4+ T cell proliferation in the presence of T cell receptor and CD28 signaling. These data suggest that PD-L2 on DCs protects against autoreactive CD4+ T cell expansion and severe inflammation in mice with EAM.

Entities:  

Keywords:  EAM; PD-L2; autoimmunity; cardio-oncology; immune checkpoint; myocarditis

Year:  2021        PMID: 33572655      PMCID: PMC7866985          DOI: 10.3390/ijms22031426

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  32 in total

1.  An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow.

Authors:  M B Lutz; N Kukutsch; A L Ogilvie; S Rössner; F Koch; N Romani; G Schuler
Journal:  J Immunol Methods       Date:  1999-02-01       Impact factor: 2.303

Review 2.  Pathogenesis and diagnosis of myocarditis.

Authors:  Chantal Elamm; DeLisa Fairweather; Leslie T Cooper
Journal:  Heart       Date:  2012-03-22       Impact factor: 5.994

Review 3.  Update on myocarditis.

Authors:  Ingrid Kindermann; Christine Barth; Felix Mahfoud; Christian Ukena; Matthias Lenski; Ali Yilmaz; Karin Klingel; Reinhard Kandolf; Udo Sechtem; Leslie T Cooper; Michael Böhm
Journal:  J Am Coll Cardiol       Date:  2012-02-28       Impact factor: 24.094

4.  Endothelin receptor antagonist exacerbates autoimmune myocarditis in mice.

Authors:  Kazuko Tajiri; Satoshi Sakai; Taizo Kimura; Tomoko Machino-Ohtsuka; Nobuyuki Murakoshi; Dongzhu Xu; Zheng Wang; Akira Sato; Takashi Miyauchi; Kazutaka Aonuma
Journal:  Life Sci       Date:  2014-01-18       Impact factor: 5.037

5.  Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice.

Authors:  H Nishimura; T Okazaki; Y Tanaka; K Nakatani; M Hara; A Matsumori; S Sasayama; A Mizoguchi; H Hiai; N Minato; T Honjo
Journal:  Science       Date:  2001-01-12       Impact factor: 47.728

6.  Exacerbation of autoimmune myocarditis by an immune checkpoint inhibitor is dependent on its time of administration in mice.

Authors:  Kenjiro Tsuruoka; Shigeo Wakabayashi; Hirofumi Morihara; Ninso Matsunaga; Yasuhito Fujisaka; Isao Goto; Akihisa Imagawa; Michio Asahi
Journal:  Int J Cardiol       Date:  2020-04-13       Impact factor: 4.164

7.  Cardiac myosin induces myocarditis in genetically predisposed mice.

Authors:  N Neu; N R Rose; K W Beisel; A Herskowitz; G Gurri-Glass; S W Craig
Journal:  J Immunol       Date:  1987-12-01       Impact factor: 5.422

8.  Pitavastatin regulates helper T-cell differentiation and ameliorates autoimmune myocarditis in mice.

Authors:  Kazuko Tajiri; Nobutake Shimojo; Satoshi Sakai; Tomoko Machino-Ohtsuka; Kyoko Imanaka-Yoshida; Michiaki Hiroe; Yusuke Tsujimura; Taizo Kimura; Akira Sato; Yasuhiro Yasutomi; Kazutaka Aonuma
Journal:  Cardiovasc Drugs Ther       Date:  2013-10       Impact factor: 3.727

9.  Dendritic cell-induced autoimmune heart failure requires cooperation between adaptive and innate immunity.

Authors:  Urs Eriksson; Romeo Ricci; Lukas Hunziker; Michael O Kurrer; Gavin Y Oudit; Tania H Watts; Ivo Sonderegger; Kurt Bachmaier; Manfred Kopf; Josef M Penninger
Journal:  Nat Med       Date:  2003-11-16       Impact factor: 53.440

Review 10.  Cardiac Complications in Immune Checkpoint Inhibition Therapy.

Authors:  Kazuko Tajiri; Masaki Ieda
Journal:  Front Cardiovasc Med       Date:  2019-01-23
View more
  2 in total

Review 1.  Myocarditis Induced by Immunotherapy in Metastatic Melanoma-Review of Literature and Current Guidelines.

Authors:  Anna M Czarnecka; Marcin Kleibert; Iga Płachta; Paweł Rogala; Michał Wągrodzki; Przemysław Leszek; Piotr Rutkowski
Journal:  J Clin Med       Date:  2022-09-01       Impact factor: 4.964

2.  [Research Progress of Immune Checkpoint Inhibitor-associated Myocarditis].

Authors:  Yunwei Liu; Yanxin Chen; Zhimin Zeng; Anwen Liu
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2021-09-15
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.